Compare RYN & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYN | BLCO |
|---|---|---|
| Founded | 1926 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Ophthalmic Goods |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.4B |
| IPO Year | 1994 | 2022 |
| Metric | RYN | BLCO |
|---|---|---|
| Price | $21.57 | $16.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $26.00 | $18.45 |
| AVG Volume (30 Days) | ★ 2.1M | 417.0K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | ★ 11.73% | N/A |
| EPS Growth | ★ 26.78 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $484,485,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | $214.97 | $8.65 |
| Revenue Next Year | $10.35 | $5.59 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $19.49 | $13.53 |
| 52 Week High | $27.34 | $18.92 |
| Indicator | RYN | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 50.52 | 56.83 |
| Support Level | $20.98 | $16.74 |
| Resistance Level | $21.85 | $17.61 |
| Average True Range (ATR) | 0.56 | 0.54 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 38.93 | 76.45 |
Rayonier Inc is a timberland real estate investment trust engaged in the ownership, management, and investment of timberlands. The company operates through Southern Timber, Pacific Northwest Timber, and Real Estate segments. The Southern Timber and Pacific Northwest Timber segments are involved in harvesting timber and related activities, as well as value-added services such as licensing properties for hunting, leasing land for mineral extraction and communication infrastructure, land-based solutions including carbon capture and solar energy, and log trading. The Real Estate segment is engaged in land sales across various categories, as well as residential and commercial leasing activities. It generates the majority of its revenue from the Southern Timber segment.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.